
Cue Biopharma CUE
$ 0.18
-1.61%
Annual report 2025
added 03-16-2026
Cue Biopharma Total Current Liabilities 2011-2026 | CUE
Annual Total Current Liabilities Cue Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.5 M | 13.7 M | 17.1 M | 11.5 M | 12.8 M | 16.3 M | 11.7 M | 6.22 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.1 M | 6.22 M | 12.8 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alnylam Pharmaceuticals
ALNY
|
1.47 B | $ 330.34 | 3.6 % | $ 43.3 B | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
5.04 M | $ 2.96 | -1.0 % | $ 252 M | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Allena Pharmaceuticals
ALNA
|
15.7 M | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
58 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
6.18 M | - | 10.36 % | $ 9.8 M | ||
|
Aquestive Therapeutics
AQST
|
47.6 M | $ 4.09 | -0.97 % | $ 437 M | ||
|
Aravive
ARAV
|
22.1 M | - | -13.39 % | $ 1.45 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
36.4 M | $ 8.22 | 2.37 % | $ 225 M | ||
|
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | ||
|
Celldex Therapeutics
CLDX
|
51 M | $ 31.37 | 1.0 % | $ 2.08 B | ||
|
Avenue Therapeutics
ATXI
|
1.1 M | - | -52.27 % | $ 4.45 M | ||
|
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | ||
|
Axcella Health
AXLA
|
14.1 M | - | -16.42 % | $ 249 M | ||
|
Arcutis Biotherapeutics
ARQT
|
130 M | $ 23.66 | 0.11 % | $ 3.01 B | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
200 M | - | - | $ 546 M | ||
|
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
1.66 M | - | -5.38 % | $ 6.06 M | ||
|
Ardelyx
ARDX
|
88.6 M | $ 5.97 | 0.51 % | $ 1.44 B | ||
|
Atreca
BCEL
|
16.3 M | - | -11.76 % | $ 5.79 M | ||
|
CASI Pharmaceuticals
CASI
|
13.2 M | - | - | $ 35.4 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
ChemoCentryx
CCXI
|
63 M | - | - | $ 3.74 B | ||
|
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M |